Bicara Therapeutics Inc. Common Stock (BCAX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 103
- Market Cap
- $1.7B
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
SentiSense also tracks daily options readings for Bicara Therapeutics Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Bicara Therapeutics Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.